European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of…

PR NEWSWIRE

About M Fund

SITE ADMIN